The role of mindfulness training in reducing rumination in recurrent depressio

Not Applicable

Completed

• Conditions: Recurrent major depressive disorder; Mental and Behavioural Disorders; Recurrent depressive disorder

• Registration Number: ISRCTN18001392
• Lead Sponsor: niversity of Bergen

Brief Summary

2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32503649/ results (added 08/06/2020) 2019 Other publications in https://pubmed.ncbi.nlm.nih.gov/31695636/ (added 03/01/2023) 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/35330721/ (added 03/01/2023) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38312915/ Secondary analyses (added 05/02/2024)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-11-22
• Study Completion: 2018-12-31
• Last Update Posted: 19 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

Clinical group:
1. Age: 18 - 70 years old
2. Both genders
3. At least three previous depressive episodes, and to currently fulfill the diagnostic criteria for recurrent depression, and in full/partial remission from depression
4. Patients may continue on antidepressant while participating in the study. It is, however, important that they do not discontinue or change dosage of medication while receiving the interventions of MBCT
5. No current neurological, cardiac or hormonal diseases
6. Borderline Personality Disorder (as assessed by SCID-II)

Healthy control group:
1. Age: 18-70 years old
2. No current or prior psychiatric illness (as indicated by M.I.N.I.)
3. No current neurological, cardiac or hormonal diseases

Exclusion Criteria

1. Acute suicidal danger, a lifetime history of psychosis/schizophrenia, bipolar disorder, substance use disorders
2. Ongoing or mindfulness based treatment past 2 years
3. Ongoing psychotherapy
4. Pregnant/lactating

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Attention regulation processes will be the primary outcome measures. Intra-individual variability in reaction times and default mode activity during cognitive control processing will be used as measures of attentional lapses. Attentional lapses and cognitive control will be measured with performance based test measures. In a subsample brain activation will be measured using functional Magnetic Resonance Imaging (fMRI). Further, self-reported questionnaire data will be applied to measure the degree of ruminative thought (RRQ), and the correlation between intra-individual variance of reaction times, Default Mode activity and ruminative thought processes. Heart Rate Variability (HRV) will be used as a psychophysiological measure of cognitive control.<br><br>All the outcome measures are administered at baseline and at 8 weeks following post treatment. The primary outcome of level of rumination (RRQ) is also measured after 6 months, 1, and 2 years.